WO2000029405A1 - Procede de preparation du (2s)-1-[(2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulfonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide - Google Patents
Procede de preparation du (2s)-1-[(2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulfonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide Download PDFInfo
- Publication number
- WO2000029405A1 WO2000029405A1 PCT/FR1999/002759 FR9902759W WO0029405A1 WO 2000029405 A1 WO2000029405 A1 WO 2000029405A1 FR 9902759 W FR9902759 W FR 9902759W WO 0029405 A1 WO0029405 A1 WO 0029405A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyethylene glycol
- compound
- reaction
- formula
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a new process for the preparation of (2S) -1- [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1- (3, 4-dimethoxybenzenesulfonyl) -3-hydroxy-2 , 3-dihydro-lff-indole-2-carbonyl] pyrrolidine-2-carboxamide, its solvates and / or hydrates.
- compound A hereinafter referred to as compound A, is to date, non-peptide antagonist the strongest and most selective of V ⁇ receptors 1 arginine-vasopressin in different species, particularly human Via receptor (C. Serradeil-Le Gai et al., J. Clin. Invest., 1993, 92, 224-231) and, consequently, is useful in particular in the treatment of affections of the cardiovascular system, of the central nervous system, of the renal system, of the gastric system, as well as an antiemetic or antiproliferative agent or, in women, to treat dysmenorrhea or premature labor.
- V ⁇ receptors 1 arginine-vasopressin in different species, particularly human Via receptor (C. Serradeil-Le Gai et al., J. Clin. Invest., 1993, 92, 224-231) and, consequently, is useful in particular in the treatment of affections of the cardiovascular system, of the central nervous system, of the renal system, of the gastric system, as well as an anti
- compound B hereinafter referred to as compound B.
- Each of the cis optical isomers is differentiated and characterized in accordance with the analytical method and methods described in document EP 0 526 348.
- An X-ray analysis made it possible to define the absolute configuration of one of the cis optical isomers, that of the other cis optical isomer being deduced therefrom.
- each of the trans optical isomers was isolated and characterized. However, their absolute configuration has not been determined.
- the process for preparing compound A as described in the prior art consists in reacting (2S) -l- ⁇ [[4-chloro-2- (2-chlorobenzoyl) phenyl] - (3 , 4-dimethoxybenzenesulfonyl) amino] acetyl ⁇ pyrrolidine-2-carboxamide (compound B) with 1, 8-diazabicyclo [5.4.0] undec- 7-ene in methanol, for 60 hours and at a temperature of -10 ° C to provide the mixture of the four optical isomers of the compound of formula (III).
- this method has disadvantages, sometimes sufficient to exclude it from any use on an industrial scale.
- compound A prepared by this process is obtained in low yields.
- compound A was in fact obtained with final yields of between 12 and 20% calculated from compound B.
- this process uses as base to carry out the cyclization, the 1, 8-diazabicyclo [5.4.0] undec-7-ene which is expensive and which, moreover, is toxic, excluding its use on the scale industrial.
- the process according to the invention uses inexpensive and non-toxic compounds and makes it possible to considerably reduce the reaction times.
- the subject of the present invention is a process for the preparation of (2S) -1- [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1- (3, 4-dimethoxybenzene sulfonyl) -3-hydroxy- 2,3-dihydro-lf-indole-2-carbonyl] pyrrolidine-2-carboxamide, its solvates and / or hydrates, of formula:
- the polyethylene glycol (PEG) of an average molecular weight between 200 and 600 used in the above process can be a polyethylene glycol of a given average molecular weight or else a mixture of polyethylene glycols of various average molecular weight.
- polyethylene glycol 200 or "PEG 200”, polyethylene glycol 400 or “PEG 400”, or polyethylene glycol 600 or “PEG 600” are preferred. Particularly, it is preferred, according to the invention, to use polyethylene glycol 400 or "PEG 400".
- the polyethyleneglycol / water mixture used in the process of the invention contains 0.1 to 1 volume of water per volume of polyethyleneglycol.
- a mixture containing 0.4 to 0.5 volume of water per volume of polyethylene glycol is used.
- the polyethylene glycol / water mixture is used in an amount of 2 to 10 equivalents by volume per equivalent by weight of compound of formula (II). Preferably, the mixture is used in an amount of 2 to 5 equivalents by volume per equivalent by weight of compound of formula (II).
- the alkali metal hydroxide used to carry out the cyclization is chosen from sodium hydroxide, potassium hydroxide or lithium hydroxide. Preferably, sodium hydroxide is used.
- the alkali metal hydroxide takes part in the reaction at a rate of 0.1 to 10 molar equivalents per molar equivalent of compound of formula (II), preferably from 0.9 to 1.2 molar equivalents.
- the reaction according to the invention is carried out at a temperature between 0 ° C and 45 ° C.
- the reaction mixture is neutralized, preferably at a pH of between 5.5 and 7.
- Neutralization is carried out by adding a mineral or organic acid, such as hydrochloric acid, sulfuric acid, potassium hydrogen sulphate, acetic acid, to the reaction mixture, said acids being in solution in water or in water in the presence of a water-miscible solvent, such as an alcohol, ethanol for example, and at a temperature between 0 ° C and room temperature (about 20 to 25 ° VS) .
- a mineral or organic acid such as hydrochloric acid, sulfuric acid, potassium hydrogen sulphate, acetic acid
- a water-miscible solvent such as an alcohol, ethanol for example
- the temperature of the reaction medium is raised to 15-17 ° C by circulation of cold water in the jacket and left stirring for 1 hour at this temperature.
- a control by HPLC shows that the mixture at the end of the reaction contains:
- the reaction medium is brought to reflux (T ⁇ 81.1 ° C) and left for 10 minutes with stirring at reflux. Cool to 55 ° C, seed the medium by adding a suspension of 0.391 kg of compound A in 1 liter of water, and keep under minimum stirring at 54-55 ° C for 1 hour. The temperature of the medium is gradually brought to 20 ° C. with a cooling ramp of 10 ° C. / hour and with minimum stirring, then left overnight with stirring at 20-22 ° C.
- reaction medium is cooled to 10 ° C., compound A is filtered off in suspension, washed twice the product obtained with 32 liters of a denatured ethanol solution with toluene / purified water (70/30; v / v) and dried under vacuum at 80 ° C.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000582392A JP2002530281A (ja) | 1998-11-16 | 1999-11-10 | (2s)−1−[(2r,3s)−5−クロロ−3−(2−クロロフェニル)−1−(3,4−ジメトキシベンゼンスルホニル)−3−ヒドロキシ−2,3−ジヒドロ−1h−インドール−2−カルボニル]ピロリジン−2−カルボキサミドの製造法 |
US09/831,721 US6355809B1 (en) | 1998-11-16 | 1999-11-10 | Method for preparing (2s)-1-(2r3s)-5-chloro-3-(2-chlorophenyl) -1-(3,4-dimethoxy benzene-sulphonyl) 3-hydroxy-2,3-dihydro-1h-indole-2-carbonyl pyrrolidine-2-carboxamide |
AU11659/00A AU1165900A (en) | 1998-11-16 | 1999-11-10 | Method for preparing (2s)-1-( (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl) pyrrolidine-2- carboxamide |
EP99972213A EP1131317A1 (fr) | 1998-11-16 | 1999-11-10 | Procede de preparation du (2s)-1- (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulfonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide |
CA002348676A CA2348676A1 (fr) | 1998-11-16 | 1999-11-10 | Procede de preparation du (2s)-1-¬(2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulfonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl| pyrrolidine-2- carboxamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9814384A FR2786486B3 (fr) | 1998-11-16 | 1998-11-16 | Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates |
FR98/14384 | 1998-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000029405A1 true WO2000029405A1 (fr) | 2000-05-25 |
Family
ID=9532788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/002759 WO2000029405A1 (fr) | 1998-11-16 | 1999-11-10 | Procede de preparation du (2s)-1-[(2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulfonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide |
Country Status (7)
Country | Link |
---|---|
US (1) | US6355809B1 (fr) |
EP (1) | EP1131317A1 (fr) |
JP (1) | JP2002530281A (fr) |
AU (1) | AU1165900A (fr) |
CA (1) | CA2348676A1 (fr) |
FR (1) | FR2786486B3 (fr) |
WO (1) | WO2000029405A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100374420C (zh) * | 2002-03-06 | 2008-03-12 | 阿斯特拉曾尼卡有限公司 | 具有糖原磷酸化酶抑制活性的吲哚酰胺衍生物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05013478A (es) * | 2003-06-10 | 2006-03-09 | Pfizer | Combinaciones terapeuticas. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526348A1 (fr) * | 1991-08-02 | 1993-02-03 | Sanofi | Dérivés d'indoline portant une fonction amidique, leur préparation, les compositions pharmaceutiques en contenant |
FR2756736A1 (fr) * | 1996-12-05 | 1998-06-12 | Sanofi Sa | Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338755A (en) * | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
US5481005A (en) * | 1990-07-31 | 1996-01-02 | Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
-
1998
- 1998-11-16 FR FR9814384A patent/FR2786486B3/fr not_active Expired - Lifetime
-
1999
- 1999-11-10 JP JP2000582392A patent/JP2002530281A/ja not_active Ceased
- 1999-11-10 US US09/831,721 patent/US6355809B1/en not_active Expired - Fee Related
- 1999-11-10 EP EP99972213A patent/EP1131317A1/fr not_active Withdrawn
- 1999-11-10 CA CA002348676A patent/CA2348676A1/fr not_active Abandoned
- 1999-11-10 AU AU11659/00A patent/AU1165900A/en not_active Abandoned
- 1999-11-10 WO PCT/FR1999/002759 patent/WO2000029405A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526348A1 (fr) * | 1991-08-02 | 1993-02-03 | Sanofi | Dérivés d'indoline portant une fonction amidique, leur préparation, les compositions pharmaceutiques en contenant |
FR2756736A1 (fr) * | 1996-12-05 | 1998-06-12 | Sanofi Sa | Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100374420C (zh) * | 2002-03-06 | 2008-03-12 | 阿斯特拉曾尼卡有限公司 | 具有糖原磷酸化酶抑制活性的吲哚酰胺衍生物 |
Also Published As
Publication number | Publication date |
---|---|
AU1165900A (en) | 2000-06-05 |
CA2348676A1 (fr) | 2000-05-25 |
FR2786486A1 (fr) | 2000-06-02 |
FR2786486B3 (fr) | 2000-12-08 |
US6355809B1 (en) | 2002-03-12 |
JP2002530281A (ja) | 2002-09-17 |
EP1131317A1 (fr) | 2001-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2343275B1 (fr) | Forme cristalline des énantiomères optiques du modafinil. | |
WO1992020654A1 (fr) | Nouveaux derives de perhydroisoindole et leur preparation | |
EP0515541B1 (fr) | PROCEDE DE PREPARATION DE L'ACIDE CIS-$g(b)-PHENYLGLYCIDIQUE-(2R,3R) | |
FR2640972A1 (fr) | ||
EP0406112B1 (fr) | 1-Benzhydrylazétidines, leur préparation et leur application comme intermédiaires pour la préparation de composés à activité antimicrobienne | |
EP0309324A1 (fr) | Procédé de synthèse d'alpha amino N alkyles et de leurs esters. Application à la synthèse de carboxyalkyl dipeptides | |
WO2000029405A1 (fr) | Procede de preparation du (2s)-1-[(2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulfonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide | |
FR2552081A1 (fr) | Procede de preparation de prolines substituees | |
CA1250313A (fr) | PROCEDE DE PREPARATION DE COMPOSES INSATURES CHLORES EN .alpha. DE DEUX GROUPEMENTS ELECTROATTRACTEURS EN POSITION .beta. | |
EP1620390B1 (fr) | Procede de synthese de la 4-hydroxyisoleucine et de ses derives | |
EP0409712A1 (fr) | Procédé de préparation d'un diastéréoisomère d'esters glycidiques, composés intermédiaires et procédé de préparation de dérivés de benzothiazépine-one | |
WO1996038447A1 (fr) | Derives du 2-azabicyclo[2.2.1]heptane, leur preparation et leur application | |
EP0923567A1 (fr) | Derives de benzylamine, leur preparation et leur application en therapeutique | |
EP0687683B1 (fr) | Procédé de synthèse d'halogénoalkylferrocènes | |
EP0478417B1 (fr) | Procédé de synthèse de monohalogénoalkylferrocènes | |
FR2546889A1 (fr) | Procede de preparation d'un acide aminolactonecarboxylique | |
EP0414686B1 (fr) | Derives de trifluoromethyl-1-tetralines, leur preparation et leur application pour la synthese de composes presentant des proprietes therapeutiques | |
EP1131293A1 (fr) | Derives de 1-aminoethylquinoleine pour le traitement de l'incontinence urinaire | |
EP0346240A1 (fr) | Nouveaux dérivés de la phénothiazine, leur préparation et les compositions qui les contiennent | |
WO2005030719A1 (fr) | Nouveau procede de preparation du cis-octahydro-isoindole | |
EP0563219B1 (fr) | Procede de preparation de derives "syn" du propanamide | |
WO2005030718A1 (fr) | Nouveau procede de preparation du cis-octahydro-isoindole | |
EP0828740A1 (fr) | Derives du 2-azabicyclo(2.2.1)heptane, leur preparation et leur application | |
FR2474025A1 (fr) | Nouveaux alcools non satures et leur utilisation dans la preparation d'oxolanes | |
FR2727681A1 (fr) | Procede de preparation de derives de pyrrolizine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2000 11659 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2348676 Country of ref document: CA Kind code of ref document: A Ref document number: 2348676 |
|
ENP | Entry into the national phase |
Ref document number: 2000 582392 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999972213 Country of ref document: EP Ref document number: 09831721 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999972213 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999972213 Country of ref document: EP |